

Applicant: Co. [REDACTED] et al.
Serial No.: Not yet assigned
Filed: Herewith
Page 2

6. (Amended) A compound according to Claim 1, wherein R7, R8 and R9 are alkyl or alkenyl radicals with from 1 to 7 carbon atoms.
7. (Amended) A compound according to Claim 1, wherein R10 is an alkyl radical with from 1 to 20 carbon atoms.
8. (Amended) A compound according to Claim 1, wherein R2 is an alkyl or alkenyl group with from 1 to 7 carbon atoms.
9. (Amended) A compound according to Claim 1, wherein Y is an alkylene radical with from 2 to 20 carbon atoms.
10. (Amended) A compound according to Claim 1, wherein X is a cycloalkyl-ether or thio-ether, having a ring with 5 or 6 members.
11. (Amended) A compound according to Claim 1, wherein R11 or R12 is an alkyl or alkenyl radical with from 1 to 25 carbon atoms.
12. (Amended) A compound according to Claim 1, wherein R7 and R8 form, together with the nitrogen atoms to which they are bound, a ring having from 5 to 7 members.
13. (Amended) A compound according to Claim 1, wherein the -NR12R13 group is selected from the group consisting of: piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl and hydroxyethylpiperazinyl groups.
14. (Amended) A compound according to Claim 1, wherein R14 is an alkylene radical with from 1 to 10 carbon atoms.
15. (Amended) A compound according to Claim 1, wherein R15 is an alkyl or alkenyl radical with from 1 to 7 carbon atoms.

100330061-010402

A1

Applicant: Co. et al.
Serial No.: Not yet assigned
Filed: Herewith
Page 3

16. (Amended) A medicament comprising the compound according to Claim 1.

17. (Amended) A drug with agonist activity in relation to a CB2 cannabinoid receptor comprising the compound according to Claim 16.

A1

18. (Amended) A drug for the treatment of inflammatory processes or inflammatory processes with a hyperalgetic component, each process having a neurogenic basis or an immunogenic basis, each basis being associated with an immuno-inflammatory condition, a neurodegenerative pathological condition, or a pathological condition in which a non-psychomimetic effect of cannabinoids mediated either by CB2 receptors or by peripheral CB1 receptors is noted.

19. (Amended) A cosmetic additive comprising the compound according to Claim 1.

20. (New) A compound according to Claim 4, wherein R1 is a saturated or mono-unsaturated alkyl radical with from 13 to 15 carbon atoms.

A2

21. (New) A compound according to Claim 5, wherein R4 is a saturated or mono-unsaturated alkylene radical with from 6 to 14 carbon atoms.

22. (New) A compound according to Claim 6, wherein R7, R8 and R9 are methyl groups.

23. (New) A compound according to Claim 9, wherein Y is an alkylene radical with 2 to 6 carbon atoms.

24. (New) A compound according to Claim 10, wherein the members are selected from the group consisting of: tetrahydropyran-2-yl, tetrahydrofuran-2-yl, tetrahydrothiopyran-2-yl, tetrahydrothiofuran-2-yl, 4-methoxytetrahydropyran-2-yl, and 1,4-dioxan-2-yl.

1003300001.010402